1. Home
  2. LPCV vs PROF Comparison

LPCV vs PROF Comparison

Compare LPCV & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPCV

Launchpad Cadenza Acquisition Corp I Class A Ordinary Share

N/A

Current Price

$10.13

Market Cap

286.1M

Sector

N/A

ML Signal

N/A

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.75

Market Cap

263.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPCV
PROF
Founded
2025
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
286.1M
263.8M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
LPCV
PROF
Price
$10.13
$6.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
26.3K
117.9K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.89
EPS
N/A
N/A
Revenue
N/A
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
N/A
$64.10
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.73
52 Week Low
$9.89
$3.92
52 Week High
$10.13
$8.95

Technical Indicators

Market Signals
Indicator
LPCV
PROF
Relative Strength Index (RSI) 75.17 40.09
Support Level $9.97 $6.17
Resistance Level N/A $7.03
Average True Range (ATR) 0.02 0.52
MACD 0.01 -0.11
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
LPCV
PROF

About LPCV Launchpad Cadenza Acquisition Corp I Class A Ordinary Share

Launchpad Cadenza Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: